Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635326 | 0.87 | HPGD (0.35) | HPGDHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4865356 | 0.81 | HTR2A (0.42) | HPGDHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL5634825 | 0.81 | HTR2A (0.33) | HPGDHTR2AHTR2CHTR2B | |
| SCHEMBL5635808 | 0.74 | TDP1 (0.30) | TDP1 | |
| SCHEMBL5635954 | 0.71 | HTR2A (0.36) | HPGDHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL5635950 | 0.71 | HTR2A (0.36) | HPGDHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL5636994 | 0.71 | POLB (0.37) | HPGDHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL4874577 | 0.69 | HPGD (0.41) | HPGDMAPTKMT2AALDH1A1 | |
| SCHEMBL5636810 | 0.68 | HPGD (0.47) | HPGDMAPTKMT2AALDH1A1CYP1A2 | |
| SCHEMBL11182919 | 0.68 | PDE7A (0.56) | HPGDMAPTKMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054912-A1 | Modulators of acetylcholine receptors | ASTLES PETER C | 2007-03-08 | — | — | US | disclosed |
| US-7148236-B2 | Modulators of acetylcholine receptors | MERCK & CO., INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050182088-A1 | Modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182088-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | HPGD 910/4885HTR2A 311/4885HTR2C 310/4885 |
| US-20070054912-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | HPGD 1160/4885HTR2A 326/4885HTR2C 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.